DUX4 and sarcoma: Using our published chromatin profiling studies (Chromatin immunoprecipitation followed by sequencing, ChIP-Seq) from patient-derived CIC::DUX4 fusion positive sarcoma cells (NCC_CDS1_X1_C1), we identified 392 high-confidence targets (FDR q < 0.001) that overlap with CIC binding peaks [13].